X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs VENUS REMEDIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA VENUS REMEDIES TORRENT PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 45.5 -3.4 - View Chart
P/BV x 6.2 0.1 4,911.7% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
VENUS REMEDIES
Mar-18
TORRENT PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,550126 1,231.1%   
Low Rs1,14461 1,871.5%   
Sales per share (Unadj.) Rs354.7301.8 117.5%  
Earnings per share (Unadj.) Rs40.1-24.9 -161.1%  
Cash flow per share (Unadj.) Rs64.22.5 2,523.8%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1293.3 93.1%  
Shares outstanding (eoy) m169.2212.34 1,371.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.80.3 1,225.6%   
Avg P/E ratio x33.6-3.8 -893.9%  
P/CF ratio (eoy) x21.036.7 57.1%  
Price / Book Value ratio x4.90.3 1,546.6%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8971,154 19,752.0%   
No. of employees `00014.70.9 1,589.2%   
Total wages/salary Rs m11,353393 2,887.9%   
Avg. sales/employee Rs Th4,083.04,026.1 101.4%   
Avg. wages/employee Rs Th772.3425.0 181.7%   
Avg. net profit/employee Rs Th461.3-331.8 -139.0%   
INCOME DATA
Net Sales Rs m60,0213,724 1,611.7%  
Other income Rs m2,98823 13,281.8%   
Total revenues Rs m63,0093,747 1,681.8%   
Gross profit Rs m13,493395 3,417.6%  
Depreciation Rs m4,086338 1,207.8%   
Interest Rs m3,085354 870.7%   
Profit before tax Rs m9,310-275 -3,381.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,52932 8,002.2%   
Profit after tax Rs m6,781-307 -2,209.6%  
Gross profit margin %22.510.6 212.0%  
Effective tax rate %27.2-11.5 -236.6%   
Net profit margin %11.3-8.2 -137.1%  
BALANCE SHEET DATA
Current assets Rs m52,6232,638 1,995.1%   
Current liabilities Rs m52,0222,305 2,257.2%   
Net working cap to sales %1.08.9 11.2%  
Current ratio x1.01.1 88.4%  
Inventory Days Days120135 88.3%  
Debtors Days Days7646 164.5%  
Net fixed assets Rs m85,0164,871 1,745.4%   
Share capital Rs m846123 685.7%   
"Free" reserves Rs m45,3763,496 1,298.1%   
Net worth Rs m46,2223,619 1,277.2%   
Long term debt Rs m41,1151,374 2,991.5%   
Total assets Rs m142,4327,509 1,896.9%  
Interest coverage x4.00.2 1,802.0%   
Debt to equity ratio x0.90.4 234.2%  
Sales to assets ratio x0.40.5 85.0%   
Return on assets %6.90.6 1,097.3%  
Return on equity %14.7-8.5 -173.0%  
Return on capital %14.21.6 897.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m14,5800-   
Fx outflow Rs m3,600517 697.0%   
Net fx Rs m10,980-517 -2,125.9%   
CASH FLOW
From Operations Rs m8,942514 1,738.3%  
From Investments Rs m-47,070-123 38,236.8%  
From Financial Activity Rs m34,174-387 -8,828.2%  
Net Cashflow Rs m-3,6554 -87,023.8%  

Share Holding

Indian Promoters % 71.5 32.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,900.0%  
FIIs % 12.6 0.6 2,172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 66.4 13.3%  
Shareholders   26,511 20,121 131.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Retail Inflation, Growth in India's Aviation Sector, and Top Cues in Focus Today(Pre-Open)

Share markets in India witnessed buying interest during closing hours yesterday and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 13, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS